Trial to Assess the Safety and Efficacy of Sirolimus-Coated Balloon vs. Uncoated Standard Angioplasty for the Treatment of Below-the-knee Peripheral Arterial Disease

Peripheral Artery Disease Clinical Trial

— LIMES  

Official title:

Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of SiroLIMus Drug Coated Balloon Versus Non-coated Standard Angioplasty for the Treatment of Infrapopliteal Occlusions in Patients With PEripheral Arterial DiSease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04772300
• Other study ID #: ZKSJ0132
• Status: Recruiting
• Phase: N/A
• Start date: February 10, 2022
• Est. completion date: September 2028

Study information

• Verified date: March 2024
• Source: Jena University Hospital
• Contact: Ulf Teichgrarber, Prof. Dr.
• Phone: +49 3641
• Email: ulf.teichgraeber[@]med.uni-jena.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective, interventional, multicenter 1:1 randomized trial. The trial evaluates the safety and efficacy of the Magic Touch PTA sirolimus drug-coated balloon in comparison to the treatment with POBA (control device) in patients with advanced infrapopliteal artery disease.

Description:

The purpose of this study is to assess whether efficacy of the MagicTouch® Sirolimus Coated PTA Balloon Catheter (SRL-DCB) is superior and whether safety is non-inferior to Plain Old Balloon Angioplasty (POBA) regarding treatment of high-grade stenoses ≥ 75 % in the infrapopliteal arteries (located below the P3 segment of the popliteal artery to the tibiotalar joint) in patients presenting with chronic limb-threatening ische-mia (CLTI) (Rutherford 4-6).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 230
• Est. completion date: September 2028
• Est. primary completion date: December 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years at the time of consent.

2. Subject has been informed of the nature of the study, is willing to comply with all required follow-up evaluations within the defined follow-up visit windows and has signed an Ethics Committee (EC) approved consent form.

3. Female subjects of childbearing potential have a negative pregnancy test = 7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female subjects will be exempted from this requirement in case they are sterile, infertile, or have been post-menopausal for at least 12 months (no menses).

4. Life expectancy > 1 year in the investigator's opinion.

5. Subject presenting with documented chronic limb-threatening ischemia (CLTI) in the target limb defined as Rutherford category 4, 5 or 6.

6. In case of Rutherford category 5 or 6: Subjects with documented infection grade = 2 according to the wound ischemia foot infection (WIfI) classification.

7. All ischemia grades according to the wound ischemia foot infection (WIfI) classifi-cation are allowed.documented infection grade = 2 according to the wound ischemia foot infection (WIfI) classification.

7. All ischemia grades according to the wound ischemia foot infection (WIfI) classification are allowed.

8. Reference Vessel Diameter (RVD) = 2 and = 4.0 mm. 9. = 75 % stenosis or occlusion of the target vessel by visual estimate of the treating physician; no minimal lesion length required.

10. The target lesion may consist of multiple target vessel lesions, if they are = 5 cm away from each other and if at least one of them is a stenosis = 75 % and all lesions are located in only one of the infrapopliteal arteries or directly within the transition area. Non-target vessels (e.g. inflow lesions or contralateral extremity, other non-target vessels below the knee) and non-target lesions of the target ves-sel can be treated during the study index procedure but according to the patient's randomization result (interventional group: Sirolimus-coated balloon or POBA; control group: only POBA).

11. No lesion length limitation, no limitation in number of used devices. 12. The lesion must be located in the infrapopliteal arteries and above the ankle joint. Lesions may not be located above the tibioperoneal trunk or below the tibiotalar joint (arteries of the foot), nor can the treatment (investigational device or standard PTA, including pre-dilatation) extend beyond these indicated regions for more than 1 cm. Note: A target lesion can extend into the P3 segment in case it involves a straight uninterrupted lesion extending from the target vessel.

13. Presence of documented run-off to the foot (clearly visible at least one of the following run-off vessels: dorsalis pedis or pedal arch or plantar arteries by angiography). The target vessel should give direct or indirect run-off to the foot.

14. Inflow free from flow-limiting lesion confirmed by angiography. Patients with flow-limiting inflow lesions (= 50 % stenosis) can be included if the lesion(s) have been treated successfully before enrollment, with a maximum residual stenosis of = 30 % per visual assessment. If an inflow lesion must be treated within or above the P3 segment of the popliteal artery, there must be a minimum of 3 cm healthy tissue between this (treated) lesion and the infrapopliteal target lesion. Use of paclitaxel-coated devices is not permitted.

15. Successful pre-dilatation of the (entire) target lesion. Success being documented by angiographic visual estimate of = 50 % residual diameter stenosis of the target lesion and no flow limiting dissection (< Grade D dissection).

16. Participants can only be enrolled once with a single target lesion.

Exclusion criteria:

1. Subjects with major amputation of the target leg above the ankle joint.

2. Planned index limb major amputation above the ankle joint, or any other planned major surgery within 30 days pre- or post-procedure. A planned amputation includ-ing and below the ankle is accepted.

3. Recent MI or stroke < 30 days prior to the index procedure.

4. Any vascular treatment with PTX or sirolimus-coated devices 60 days prior to index procedure

5. Known or suspected active infection at the time of the index procedure (abnormal white blood cell count, fever, sepsis or positive blood culture), excluding an infection of a lower extremity wound on the target limb (corresponding to WIfI infection grad 3)

6. Subjects with neurotrophic ulcers, heel pressure ulcers or calcaneal ulcers with a risk for major amputation regarding the study leg; Subjects with uncomplicated ulcers can be included.

7. Subjects with documented active osteomyelitis of the study leg, excluding the phalanges and metatarsalia, that is beyond cortical involvement of the bone per clinical judgment

8. Subjects with systemic vasculitis, such as Lupus Erythematosus or polymyalgia rheumatica on active treatment.

9. Subjects receiving systemic corticosteroid therapy (expected dosage > 5 mg of prednisolone or equivalent, per day, during the initial 9 months after procedure) or other systemic immunosuppressant therapy.

10. Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant/antiplatelet therapies which could not be substituted, and/or sirolimus or an allergy to contrast media that cannot be adequately pre-treated prior to the index procedure.

11. The subject is currently enrolled in another investigational device, drug or biological trial.

12. Female subjects who are breast feeding at the time of enrollment

13. Significant gastrointestinal bleeding or any coagulopathy that would contraindicate the use of anti-platelet therapy

14. Prior stent(s) or bypass surgery with safety margin < 3 cm within the target vessel (including stents placed within target vessels during the index procedure prior to randomization).

15. Previous procedure with drug-coated balloons in the target vessel within 6 months prior to index procedure.

16. Stenosis = 75 % or occlusions (target lesion) located or extending in the popliteal artery or below the ankle joint space. Note: A target lesion can extend into the P3 segment in case it involves a straight lesion extending from the target vessel. Non-significant stenosis below the ankle joint can be allowed in case this is not part of the target lesion.

17. Untreated significant (= 50 % residual stenosis measured by Duplex Sonography) inflow lesion or occlusion in the ipsilateral iliac, SFA and popliteal arteries.

18. Failure to obtain a = 30 % residual stenosis in pre-existing, hemodynamically sig-nificant (= 50 % measured by Duplex Sonography) inflow lesions in the ipsilateral iliac, SFA and popliteal artery.

19. Aneurysm in the target vessel.

20. Angiographic evidence of thrombus within target vessel.

21. Pre-dilatation resulted in a major (= Grade D) flow-limiting dissection (observed on 2 orthogonal views) or residual stenosis > 50 %.

22. Use of alternative therapy, e.g. atherectomy, scoring balloon, laser, radiation therapy, stents as part of target vessel treatment. Note: Use of stents is only allowed for bailout stenting.

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Artery Disease
• Peripheral Vascular Diseases

Intervention

Combination Product:
• Percutaneous Transluminal Angioplasty (PTA) MagicTouch Sirolimus Coated PTA Balloon Catheter
PTA with an sirolimus drug-coated balloon catheter (SRL-DCB) in the infrapopliteal artery

Device:
• Percutaneous Transluminal Angioplasty (PTA) with non-coated balloon catheter (POBA)
PTA with an non-coated balloon catheter (POBA) in the infrapopliteal artery

Locations

Country	Name	City	State
Austria	AKH Wien, Universitätsklinik für Innere Medizin II, Klinische Abteilung für Angiologie	Wien
Austria	Allgemeines Krankenhaus der Stadt Wien (Wien AKH), Department of Radiology	Wien
Austria	Hanusch-Krankenhaus	Wien
Germany	Universitäts-Herzzentrum Freiburg-Bad Krozingen; Clinic for Cardiology and Angiology II	Bad Krozingen
Germany	Heart and Diabetes Center North Rhine Westphalia, Clinic for General and Interventional Cardiology/Angiology	Bad Oeynhausen	North Rhine Westphalia
Germany	Universitätsklinikum Brandenburg, Abteilung für Innere Medizin 1, Hochschulklinik für Angiologie	Brandenburg
Germany	Fürst-Stirum-Klinik Bruchsal, Klinik für Kardiologie, Angiologie, Diabetologie, Neurologie und Intensivmedizin	Bruchsal
Germany	DIAKO gGmbH, Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie	Flensburg
Germany	Universitätsklinikum Hamburg-Eppendorf, Universitäres Herz- und Gefäßzentrum Hamburg, Klinik und Poliklinik für Gefäßmedizin	Hamburg
Germany	Universitätsklinikum Heidelberg, Medizinische Klinik III, Kardiologie, Angiologie und Pneumologie	Heidelberg
Germany	Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie	Jena
Germany	University Hospital Leipzig	Leipzig
Germany	Bonifatius-Hospital Lingen (Ems)	Lingen
Germany	St. Franziskus-Hospital GmbH Klinik für Gefäßchirurgie	Münster
Germany	Universitätsklinikum Münster, Klinik für Kardiologie I, Koronare Herzkrankheit, Herzinsuffizienz und Angiologie	Münster
Germany	Elblandklinikum Radebeul, Gefäßzentrum	Radebeul
Germany	Krankenhaus Barmherzige Brüder Regensburg, Institut für Radiologie, Neuroradiologie und Nuklearmedizin	Regensburg
Germany	Schön Klinik Rendsburg, Institut für Diagnostische und Interventionelle Radiologie/Neuroradiologie	Rendsburg
Germany	Elblandklinikum Riesa, Gefäßzentrum	Riesa
Germany	MEDINOS-Kliniken Sonneberg, Gefäßzentrum	Sonneberg
Germany	Kreiskrankenhaus Torgau	Torgau
Germany	University Hospital Tuebingen, Diagnostic and Interventional Radiology	Tuebingen	Baden-Württemberg
Germany	GRN Klinik Weinheim, Kardiologie/Angiologie	Weinheim

Sponsors (5)

Lead Sponsor	Collaborator
Jena University Hospital	Center for Clinical Studies, University Hospital Jena, Concept Medical Inc., CoreLab Black Forest, Vascuscience

Countries where clinical trial is conducted

Austria,  Germany, 

References & Publications (1)

Teichgraber U, Platzer S, Lehmann T, Ingwersen M, Aschenbach R, Beschorner U, Scheinert D, Zeller T. Sirolimus-Coated Balloon Angioplasty of Infra-popliteal Lesions for the Treatment of Chronic Limb-Threatening Ischemia: Study Protocol for the Randomized Controlled LIMES Study. Cardiovasc Intervent Radiol. 2022 Nov;45(11):1716-1724. doi: 10.1007/s00270-022-03213-z. Epub 2022 Jul 29. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	composite of limb salvage and primary patency at 6 months	composite of limb salvage and primary patency at 6 months. Primary patency is defined as absence of target lesion restenosis = 75 % or re-occlu-sion with restoration of in-line flow to the ankle as determined by duplex ultrasound without clinically driven target lesion revascularization (CD-TLR) after index procedure.; Clinically driven TLR is defined as revascularization due to restenosis of = 50 % in the target lesion and; Deterioration of Rutherford Class and/or; Deterioration or persistence of wounds according to the WIfI classification wound component score	6 months after study procedure (PTA with medical product under investigation or comparator)
Secondary	MALE-POD	Major Adverse Limb Events (MALE) with perioperative all-cause death (POD) at 30 days Major Adverse Limb Events (MALE) are defined as above-ankle amputation or major reintervention (i.e., new bypass graft, interposition graft revision, or thrombectomy/thrombolysis) of the treated limb involving a BTK artery.; Perioperative death (POD) is defined as death within 30 days after index proce-dure.; Major Adverse Limb Events (MALE) are defined as above-ankle amputation or major reintervention (i.e., new bypass graft, interposition graft revision, or thrombectomy/thrombolysis) of the treated limb involving a BTK artery.; Perioperative death (POD) is defined as death within 30 days after index procedure.	30 days after study procedure.
Secondary	rate of clinically-driven TVR	occurrence of clinically-driven TVR at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	TVR rate in treated target vessel and non-target vessels	Rate of all TVR including treated non-target vessel at 1, 6, 12, 24 and 36 months.	1, 6, 12, 24 and 36 months after study procedure.
Secondary	TVR rate	Rate of all TVR at 1, 6, 12, 24 and 36 months.	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Primary Patency rate	Primary Patency rate at certain time points	1, 6, 24 and 36 months after study procedure.
Secondary	Primary Patency of target and treat non-target vessel	Primary Patency rate of target and treat non-target vessel at certain time points	1, 6, 24 and 36 months after study procedure.
Secondary	Secondary Patency rate	Secondary Patency rate at certain time points	1, 6, 24 and 36 months after study procedure.
Secondary	Secondary Patency of target and treat non-target vessel	Secondary Patency rate of target and treat non-target vessel at certain time points	1, 6, 24 and 36 months after study procedure.
Secondary	Re-stenosis of >= 75% or occlusion rate	Rate of re-stenosis or re-occlusion at certain time points, defined as the absence of flow in the target vessel as determined by duplex ultrasound	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Number of treated Non-target vessels	Number of treated Non-target vessels	36 months after study procedure
Secondary	Walking Capacity Assessment 1	patient-self-assessment of walking distance at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Walking Capacity Assessment 2	VascuQoL questionnaire (Vascular Quality of Life Questionnaire) at certain time points; 25 questions (scale 1 to 7); best score 175, worst score 25.	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Target Limb Major Amputations	Rate of target limb major amputations at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	all-cause mortality	Rate of all-cause death at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Amputation free survival (AFS)	Amputation free survival (AFS) at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Amputation free survival and resolved CLTI	Amputation free survival and resolved CLTI at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Ankle-Brachial-Index (ABI)	Change in ankle-brachial index (ABI) from pre-procedure to certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Toe-Brachial-Index (TBI)	Change in toe-brachial index (TBI) from pre-procedure to certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Rutherford classification	Change in Rutherford category from pre-procedure to certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Primary sustained clinical improvement	improvement shift in the Rutherford Category of one class or more in amputation free surviving patients without the need for clinically driven TVR at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Secondary sustained clinical improvement	improvement shift in the Rutherford classification of one class or more in amputation free surviving patients including those with clinically driven TVR at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	EQ-5D-3L	Change in EQ-5D-3L (Quality of Life questionnaire) from pre-procedure to certain time points; 5 questions (scale 1 to 3), best score 5, worst score 15.	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Wound healing	Rate of wound healing from pre-procedure to certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	New or recurrent wound of the target limb	New or recurrent wound of the target limb from pre-procedure to certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Length of in-hospital-stay	Days of hospitalization at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Major Adverse Limb Events (MALE)	MALE at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	Device Success	Device Success defined as exact deployment of the device according to the instructions for use	at index procedure
Secondary	Technical Success	Technical success defined as successful vascular access and completion of the endovascular procedure with <= 50% residual diameter stenosis and restoration of in-line flow to the ankle	at index procedure
Secondary	Procedural success	30) Procedural success, defined as combination of technical success, device suc-cess and absence of major adverse events (MALE-POD, myocardial infarction, stroke) within 72 h of the index procedure).	at index procedure
Secondary	composite endpoint: patency, rate of overall-cause death and amputation-free survival	composite endpoint consisting of patency, rate of overall-cause death and amputation-free survival at certain time points	1, 6, 12, 24 and 36 months after study procedure.
Secondary	composite endpoint: rate of all-cause death, target limb major amputation and clinically-driven TLR	composite endpoint consisting of rate of all-cause death, target limb major amputation and clinically-driven Target Lesion Revascularization at certain time points	1, 6, 12, 24 and 36 months after study procedure.